Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST

被引:138
作者
Nishino, Mizuki [1 ,2 ]
Jagannathan, Jyothi P. [1 ,2 ]
Krajewski, Katherine M. [1 ,2 ]
O'Regan, Kevin [1 ,2 ]
Hatabu, Hiroto [2 ]
Shapiro, Geoffrey [3 ]
Ramaiya, Nikhil H. [1 ,2 ]
机构
[1] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA
[2] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Early Drug Dev Ctr, Dept Med Oncol, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
CT; personalized medicine; RECIST; response assessment; GASTROINTESTINAL STROMAL TUMORS; RENAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; IMATINIB MESYLATE; LUNG-CANCER; METASTATIC MELANOMA; TARGETED THERAPY; TYROSINE KINASE; EFFICACY; GUIDELINES;
D O I
10.2214/AJR.11.7483
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of this article is to review cancer-and therapy-specific tumor response assessment criteria used in clinical trials and in practice, with illustrative case examples, and to discuss future directions toward "personalized" tumor response assessment. CONCLUSION. Although Response Evaluation Criteria in Solid Tumors will remain as the primary generalized criteria for response assessment, newer cancer-and therapy-specific criteria will play an important role in providing state-of-the-art response assessment of tumor following molecular targeted therapy and will contribute to personalized cancer care in the era of molecular medicine.
引用
收藏
页码:737 / 745
页数:9
相关论文
共 58 条
[1]   Current systemic therapy for metastatic melanoma [J].
Agarwala, Sanjiv S. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (05) :587-595
[2]  
[Anonymous], 2010, CANC FACTS FIG 2010
[3]  
[Anonymous], 1979, WHO HDB REP RES CANC
[4]  
[Anonymous], NEW ENGL J MED
[5]   Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib [J].
Baccala, Angelo, Jr. ;
Hedgepeth, Ryan ;
Kaouk, Jihad ;
Magi-Galluzzi, Christina ;
Gilligan, Timothy ;
Fergany, Amr .
INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (12) :1095-1097
[6]   We should desist using RECIST, at least in GIST [J].
Benjamin, Robert S. ;
Choi, Haesun ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Charnsangavej, Chuslip .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764
[7]   Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors [J].
Benjamin, Robert S. ;
Schoffski, Patrick ;
Hartmann, Joerg Thomas ;
Van Oosterom, Allan ;
Binh Nguyen Bui ;
Duyster, Justus ;
Schuetze, Scott ;
Blay, Jean-Yves ;
Reichardt, Peter ;
Rosen, Lee S. ;
Skubitz, Keith ;
McCoy, Sheryl ;
Sun, Yu-Nien ;
Stepan, Daniel E. ;
Baker, Laurence .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) :69-77
[8]   Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].
Blanke, Charles D. ;
Rankin, Cathryn ;
Demetri, George D. ;
Ryan, Christopher W. ;
von Mehren, Margaret ;
Benjamin, Robert S. ;
Raymond, A. Kevin ;
Bramwell, Vivien H. C. ;
Baker, Laurence H. ;
Maki, Robert G. ;
Tanaka, Michael ;
Hecht, J. Randolph ;
Heinrich, Michael C. ;
Fletcher, Christopher D. M. ;
Crowley, John J. ;
Borden, Ernest C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632
[9]   Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). [J].
Camidge, D. R. ;
Bang, Y. ;
Kwak, E. L. ;
Shaw, A. T. ;
Iafrate, A. J. ;
Maki, R. G. ;
Solomon, B. J. ;
Ou, S. I. ;
Salgia, R. ;
Wilner, K. D. ;
Costa, D. B. ;
Shapiro, G. ;
LoRusso, P. ;
Stephenson, P. ;
Tang, Y. ;
Ruffner, K. ;
Clark, J. W. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[10]   Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Casali, P. G. ;
Blay, J. -Y. .
ANNALS OF ONCOLOGY, 2010, 21 :v98-v102